Format

Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):297-300. doi: 10.1007/s10096-008-0612-5. Epub 2008 Aug 21.

Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy.

Author information

1
Department of Pediatrics, Pediatric Infectious Diseases Unit, Catholic University of the Sacred Heart, L.go A. Gemelli, 8, 00168 Rome, Italy. pvalentini@rm.unicatt.it

Erratum in

  • Eur J Clin Microbiol Infect Dis.2009 Jul;28(7):879. Dosage error in article text.

Abstract

The purpose of this report is to evaluate the efficacy and safety of spiramycin/cotrimoxazole in the mother-to-child transmission of Toxoplasma gondii infection. We retrospectively analysed 76 infants born to mothers with toxoplasmosis during pregnancy and estimated the risk of mother-to-child transmission considering the gestational age at the time of infection. Seventy-six mothers were given spiramycin, cotrimoxazole and folinic acid; only two babies (2.6%) were infected by Toxoplasma and none of them showed signs or symptoms of congenital infection or interference of sulphamid on tetrahydrofolate reductase (THFR) either at birth or during follow-up. Treatment did not need to be stopped in any mother because of adverse drug effects. Our results seem to encourage the use of spiramycin/cotrimoxazole in women with toxoplasmosis during pregnancy.

PMID:
18716804
DOI:
10.1007/s10096-008-0612-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center